Application of the 1998 Canadian cholesterol guidelines to a military population: Health benefits and cost effectiveness of improved cholesterol management

Canadian Journal of Cardiology

Volumn 19, Issue 7, 2003, Pages 790-796

  Spaans, Johanna N ^a   Coyle, Douglas ^b   Fodor, George ^a   Nair, Rama ^a   Vaillancourt, Régis ^c   Grover, Steven A ^d   Coupal, Louis ^d  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c Directorate Med Plcy Pharm Plcy   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Cholesterol; Drugs; Health economics

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARMY; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SURGERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DISEASE CONTROL; DRUG COST; FAMILY HISTORY; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HYPERTENSION; LIFE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; POPULATION MODEL; PRACTICE GUIDELINE; PRESCRIPTION; REFERENCE VALUE; RISK ASSESSMENT; SMOKING; CORONARY ARTERY ATHEROSCLEROSIS; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; ECONOMICS; HYPERCHOLESTEROLEMIA; METHODOLOGY; MIDDLE AGED; RISK FACTOR; SOLDIER; STATISTICS;

CANADA; CORONARY ARTERIOSCLEROSIS; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; MILITARY PERSONNEL; PRACTICE GUIDELINES; RISK ASSESSMENT; RISK FACTORS;

EID: 0042632484     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Heart Disease and Stroke in Canada. Ottawa: Heart and Stroke Foundation of Canada, 1997.
2. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins and the risk of coronary heart disease: The Framingham Study. Ann Intern Med 1971;74:1-12.
3. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
4. Grover SA, Palmer CS, Coupal L. Serum lipid screening to identify high-risk individuals for coronary death. The results of the lipid research clinics prevalence cohort. Arch Intern Med 1994;154:679-84.
5. Frick MH, Elo O, Haapa K, et al. Helsinki heart study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med 1987;317:1237-45.
6. Lipid research clinics program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984;251:351-64.
7. Dorr AE, Gundersen K, Schneider JC Jr, Spencer TW, Martin WB. Colestipol hydrochloride in hypercholesterolemic patients: Effect on serum cholesterol and mortality. J Chronic Dis 1978;31:5-14.
8. Oliver MF, Heady JA, Morris JN, Cooper J for the committee of principle investigators. A co-operative in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069-118.
9. Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study group (WOSCOPS). Prevention of coronary disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
10. Scandinavian Simastatin Survival Study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: He Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
11. Fodor JG, McPherson R, Dafoe WA, Grenville A. Investigation and treatment of hypercholesterolemic and other dyslipidemias in Canadian primary care practice. CVD Prev 1998;1:225-30.
12. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1615-22.
13. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
14. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57.
15. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke and total mortality. An overview of randomized trials. JAMA 1997;278:313-21.
16. Frohlich J, Fodor G, McPherson R, Genest J, Langner N. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: Interim analysis. Can J Cardiol 1998;14(Suppl A):17A-21A.
17. Canadian Consensus Conference on Cholesterol. Final Report, Canadian Consensus Conference on the prevention of heart and vascular disease by altering serum cholesterol and serum lipoprotein factors. CMAJ 1988;139:II1-63.
18. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H. Estimating the benefits of modifying risk factors of cardiovascular disease: A comparison of primary versus secondary prevention. Arch Intern Med 1998;158:655-62.
19. Ramsay LE, Yeo WW, Jackson PR. Dietary reduction of serum cholesterol concentration: Time to think again. BMJ 1991;303:953-7.
20. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler CH, Neil HAW. Systematic review of dietary intervention trials to lower blood cholesterol in free-living subjects. BMJ 1998;316:1213-20.
21. Bucher HC, Griffith LE, Guyatt GH. Systematic review of the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999;19:187-95.
22. Ebrahim S, Smith GD. Systematic review of randomized controlled trials of multiple risk factor interventions for preventing coronary heart disease. BMJ 1997;314:1666-74.
23. Fodor JG, Frohlich JJ, Genest JJG, McPherson PR. Recommendations for the management and treatment of dyslipidemia. CMAJ 2000;162:1441-7.
24. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-8.
25. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600.
26. Langille DB, Joffres MR, MacPherson KM, Andreou P, Kirkland SA, MacLean DR. Prevalence of risk factors for cardiovascular disease in Canadians 55-74 years of age: Results from the Canadian Heart Health Surveys. 1986-1992. CMAJ 1999;161(Suppl 8):S3-9.
27. Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996;94:957-65.
28. Genest J Jr, Cohn JS. Clustering of cardiovascular risk factors: Targeting high-risk individuals. Am J Cardiol 1995;76:8A-20A.
29. Weber MA. Role of hypertension in coronary artery disease. Am J Nephrol 1996;16:210-6.
30. Mitchell JP. Guideline implementation in the Department of Defense. Chest 2000;118(Suppl 2):S65-9.
31. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: Evidence from a national cross sectional survey. BMJ 2000;321:1322-5.
32. EUROSPIRE I and II Group; European Action on Secondary Prevention by Intervention to Reduce Events. Clinical reality of coronary prevention guidelines: A comparison to EUROSPIRE I and II in nine countries. Lancet 2001;357:995-1001.
33. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
34. Thomas TS. Improving care with nurse case managers: Practical aspects of designing lipid clinics. Am J Cardiol 1997;80:H62-5.